Who are CC-42344's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paxlovid (Copackaged), Pf-07817883, Ximingting Tablet, ibuzatrelvir, (E) BQ-V14, PF-07321332 Dose 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cc-42344.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CC-42344 — Competitive Intelligence Brief

CC-42344 (CC-42344) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SARS-CoV-2 main protease inhibitor. Area: Infectious Disease.

phase 2 SARS-CoV-2 main protease inhibitor SARS-CoV-2 main protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CC-42344 (CC-42344) — Cocrystal Pharma, Inc.. CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CC-42344 TARGET	CC-42344	Cocrystal Pharma, Inc.	phase 2	SARS-CoV-2 main protease inhibitor	SARS-CoV-2 main protease
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Pf-07817883	pf-07817883	Pfizer	marketed	Protease inhibitor	SARS-CoV-2 main protease
Ximingting Tablet	Ximingting Tablet	Peking Union Medical College Hospital	marketed	SARS-CoV-2 main protease inhibitor	SARS-CoV-2 main protease
ibuzatrelvir	ibuzatrelvir	Pfizer	marketed	Antiviral	SARS-CoV-2 main protease (Mpro)
(E) BQ-V14	(E) BQ-V14	National Taiwan University Hospital	marketed	SARS-CoV-2 main protease inhibitor	SARS-CoV-2 main protease
PF-07321332 Dose 1	pf-07321332-dose-1	Pfizer	marketed	Protease inhibitor	SARS-CoV-2 main protease (Mpro)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (SARS-CoV-2 main protease inhibitor class)

Cocrystal Pharma, Inc. · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Minhai Biotechnology Co., Ltd · 1 drug in this class
Biota Scientific Management Pty Ltd · 1 drug in this class
Ethris GmbH · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
RSV Therapeutics LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CC-42344 — Competitive Intelligence Brief. https://druglandscape.com/ci/cc-42344. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab